青蒿明胶丸的抗疟作用研究

STUDIES ON THE ANTIMALARIAL ACTION OF CEATIN CAPSULE OF ARTEMISIA ANNUA

明胶丸对小鼠的LD_(50)剂量为162.5±10.1g(生药)/kg,对伯氏敏感株鼠疟原虫的半数转阴剂量ED_(50)为11.9±2.4g(生药)/kg,化疗指数为13.6,明胶丸的抗疟效价比青蒿素大3.5倍;对鼠疟、人间日疟的治愈率为100％,与青蒿浸膏、氯喹相同;退热时间及转阴时间均快于氯喹,但近期复燃仍较高,当延长服药天数至6d,增加日服药次数至4次或与伯氨喹伍用,可显著降低近期复燃率。该制剂生产成本大大低于青蒿素,服药量及毒副反应小于青蒿浸膏片,易于推广,病人乐于接受。

The pharmacological and clinical effects of gelatin capsulae of Artemisia annua (GCAA) were investigated.The results revealed that the LD50 WP.S 162.5±10.1g (crude drug)/kg and ED50 was 11.9±2.4g (crude drug) for clearance of parasitemia in mice infected with Plasmodium berghei therapeutic index being 13.6,which was 3.5 times more than that of artemisinin.The cure rate of COEA for Plasmodium berghei and P.vivax infections was 100%,as well as just like that of the extract tablets of Artemisia annua and chloroquines This formulation was found to be better then chloroquine in fever subsidence and disape pearance of malarial symptoms,while the recrudescence rate was still high,the latter could be inhibited by increasing therapeutic course or daily dosing time or by combination wile primaquine.